Skip to main content
Home

GBL

Main navigation

  • About GBL
      About GBL
    • Our purpose
    • Shareholding
    • Governance
      • Board of Directors
      • Board Committees
      • Corporate governance
    • ESG
      • Sustainability
      • GBL ACT
    • Risk Management
    • Business model
  • Portfolio
      Portfolio
    • Listed assets
      • 55% of GBL’s portfolio
      • adidas
      • Concentrix
      • Imerys
      • Ontex
      • Pernod Ricard
      • SGS
      • Umicore
    • Direct private assets
      • 24% of GBL’s portfolio
      • Affidea
      • Canyon
      • Parques Reunidos
      • Sanoptis
      • Voodoo
    • Indirect private assets
      • 20% of GBL’s portfolio
      • Funds
      • Co-investments
    • Third-party asset management
      • 1% of GBL’s portfolio
  • Investors
      Investors
    • GBL Share
      • Stock price & key share information
      • Dividend
      • Total Shareholder Return
      • Capital and form of shares
      • Voting rights and denominator
      • Transactions on GBL shares
    • Key Financial Information
      • Net asset value
      • Net financial position
      • Credit rating
      • Consolidated net result & Cash earnings
      • Glossary
    • Analysts
    • General Meeting
    • Financial Calendar
    • Strategic Update
    • Prospectus
  • Culture & Careers
  • Media Center
      Media Center
    • Press releases
    • Annual & Half-year reports
    • IR Presentations
    • Analyst Presentations
    • Voting rights and denominator
    • Transactions on GBL shares
    • Subscription Form
72.00 €
Stock price
06/13/202517:35
Co-investments

Flora Food Group

BDT & MSDPrevious
Human CapitalNext
Flora Food Group logo
Flora Food Group is a global leader in plant-based nutrition, with global brands such as Becel, Flora, Rama and ProActiv
€ 400 M NAV
€ 250 M Invested capital - total
15% % of GBL Capital's portfolio
Registered office
Amsterdam, Netherlands
Year of initial investment
2018

All figures are as of December 31, 2024, unless otherwise stated

Read more
Scroll to content
BDT & MSDPrevious
Human CapitalNext

Main navigation

  • About GBL
      About GBL
    • Our purpose
    • Shareholding
    • Governance
      • Board of Directors
      • Board Committees
      • Corporate governance
    • ESG
      • Sustainability
      • GBL ACT
    • Risk Management
    • Business model
  • Portfolio
      Portfolio
    • Listed assets
      • 55% of GBL’s portfolio
      • adidas
      • Concentrix
      • Imerys
      • Ontex
      • Pernod Ricard
      • SGS
      • Umicore
    • Direct private assets
      • 24% of GBL’s portfolio
      • Affidea
      • Canyon
      • Parques Reunidos
      • Sanoptis
      • Voodoo
    • Indirect private assets
      • 20% of GBL’s portfolio
      • Funds
      • Co-investments
    • Third-party asset management
      • 1% of GBL’s portfolio
  • Investors
      Investors
    • GBL Share
      • Stock price & key share information
      • Dividend
      • Total Shareholder Return
      • Capital and form of shares
      • Voting rights and denominator
      • Transactions on GBL shares
    • Key Financial Information
      • Net asset value
      • Net financial position
      • Credit rating
      • Consolidated net result & Cash earnings
      • Glossary
    • Analysts
    • General Meeting
    • Financial Calendar
    • Strategic Update
    • Prospectus
  • Culture & Careers
  • Media Center
      Media Center
    • Press releases
    • Annual & Half-year reports
    • IR Presentations
    • Analyst Presentations
    • Voting rights and denominator
    • Transactions on GBL shares
    • Subscription Form

Groupe Bruxelles Lambert (GBL)

Avenue Marnix 24
B-1000 Brussels

Contact

Reception
+32 2 289 17 86
cdumasy@gbl.com

Investor Relations

Alison Donohoe
+32 2 289 17 64
adonohoe@gbl.com
 

© 2025 GBL, all rights reserved

Footer Menu

  • Legal Notice
  • General Privacy Policy
  • Cookie policy

Made by Globule Bleu